Insider buying last 90 days
No open-market insider purchases were filed for ABSI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ABSI insider filing, plotted on the chart in Gekko.Open ABSI in Gekko
NASDAQ: ABSI
Absci (ABSI) Stock Analysis & Forecast
Oct 12 close
$9.67−0.49 (−4.8%)
Gekko Brief
AI summaryOct 12 closeAbsci draws fresh analyst attention this week as JPMorgan Chase & Co. raised its price target to $15.00 from $14.00 while reiterating an "overweight" rating, and HC Wainwright reaffirmed a "Buy" rating with a $16 price target. Both actions follow Absci's Q2 earnings miss, with a loss of $0.21 per share against a $0.19 estimate and revenue of $0.32 million versus $0.92 million expected, which had pressured shares down 5.5% earlier in the week.
Absci closes at $9.67, down 4.8% on the day, though the stock remains above both its 50-day average of $9.30 and its 200-day average of $6.06, with the shorter average also above the longer one. The GekkoIndex reads 58.2, placing it in the Neutral zone. Price sits 7.8% below Gekko Fair Value of $10.49.
The next earnings date falls on 16 November 2026, 34 days out and beyond a typical 20-trading-day hold. Seasonality from this point in the calendar shows the next 20 trading days averaging 16.9% over 5 years, with gains in 4 of those years. Analyst consensus across 8 firms stands at 7 buy and 1 hold ratings, with a consensus target of $14.40 implying 48.9% upside. No insider, Congress, or unusual options activity appears in the current windows, leaving recent price action and analyst commentary as the primary signals worth following into the report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Absci price vs fair value
Close $9.67200-day averageGekko Fair Value $10.49
Absci quick facts
- Market cap
- $1.64B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$0.79
- Revenue, TTM
- $1.56M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.28
- Volume
- 2.86M avg 4.67M
- 1-year return
- +141.1%
- Typical daily move
- ±9.6%
- Typical 20-day move
- ±16.4%
- 50-day average
- $9.30
- 200-day average
- $6.06
- Next earnings
- Nov 16
- Shares outstanding
- 171.6M
Absci swing-trade checklist
Absci scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $9.67 is above the 50-day ($9.30) and 200-day ($6.06) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
58.2, Neutral
Reading 58.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
7.8% below
Price is 7.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 16, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+16.9% on average
From this point in the calendar, the next 20 trading days averaged +16.9% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Absci stock chart and price history
Absci closed at $9.67 on Oct 12, 2026, +141.1% over the past year, inside a 52-week range of $2.24 to $12.06.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +17.8%
- 3 months
- −5.5%
- 6 months
- +217.0%
- 1 year
- +141.1%
The full ABSI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ABSI in Gekko
Follow Absci through every session
Put ABSI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ABSI in GekkoFree for 7 days. No credit card required.
About Absci
Absci is a biopharmaceutical company that works on identifying new drug targets and creating therapeutic compounds. It is known for an integrated platform that produces candidate biologic medicines along with the cell lines needed to manufacture them, combining steps that are usually handled separately in drug development.
The company supplies these outputs to collaborators, most of whom are located in the United States. Its approach centers on merging the discovery of biologic drugs with the engineering of cell lines into a single connected process, rather than treating them as distinct phases of development.
Absci was founded in 2011 and is headquartered in Vancouver, Washington. Its shares are listed on the NASDAQ under the ticker ABSI.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- absci.com
Absci GekkoIndex: the smart money zone
Absci’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.2, in the Neutral zone, up 9.6 points over five sessions.
58.2Neutral
Up 9.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 37 | +6.0% | +27.9% | ||
| Accumulation | 227 | +3.7% | +6.8% | ||
| Neutral (current zone) | 377 | +0.2% | +4.6% | ||
| Distribution | 40 | −0.6% | −4.0% | ||
| Selling | 1 | Too few readings yet | |||
Average ABSI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ABSI price, zone by zone.Track ABSI in Gekko
Is Absci stock overvalued? Gekko Fair Value
Absci trades 7.8% below Gekko Fair Value of $10.49, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Absci shares are worth, recalculated every trading day.
$10.49
Gekko Fair Value, Oct 10, 2026
7.8% Undervalued
At the end of Aug 2026 the price was 26.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ABSI in Gekko
Absci insider and Congress trading
No open-market insider purchases were filed for Absci, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ABSI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ABSI, plotted on the chart in Gekko.Open ABSI in Gekko
Absci earnings: next date and track record
Absci reports on Nov 16, 2026 (35 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 16, 2026
35 days away
- EPS estimate
- −$0.19
- Revenue estimate
- $698K
2 of 8reports beat the EPS estimate
±10.1%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 11, 2026 AI summary
- What they said
- Absci reported Q2 2026 results highlighting positive interim Phase I data for ABS-201, showing favorable safety/tolerability and a half-life supporting 2-3 injections over 6 months. Eli Lilly made a $40 million strategic investment focused on ABS-201 clinical development strategy. Absci completed a $100 million total financing from blue-chip investors in June 2026, funding pipeline development and expansion.
- Guidance
- Interim Phase IIa proof-of-concept data expected in second half of 2026, with full proof-of-concept data in early 2027. Phase II trial for endometriosis anticipated to initiate Q4 2026, with potential proof-of-concept readout in second half of 2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.21 est −$0.20 | $300K est $920K | +5.4% |
| May 7, 2026 | −$0.19 est −$0.20 | $215K est $1.26M | −0.8% |
| Nov 12, 2025 | −$0.20 est −$0.19 | $378K est $1.38M | −23.5% |
| Aug 12, 2025 | −$0.24 est −$0.19 | $593K est $5.17M | +9.5% |
| May 13, 2025 | −$0.21 est −$0.23 | $1.18M est $1.30M | −0.7% |
| Mar 18, 2025 | −$0.25 est −$0.22 | $665K est $4.87M | −7.2% |
| Nov 12, 2024 | −$0.24 est −$0.19 | $1.70M est $1.81M | −26.6% |
| Aug 14, 2024 | −$0.22 est −$0.19 | $1.27M est $1.91M | +6.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Absci stock forecast and analyst price targets
Analysts’ average 12-month price target for Absci is $14.40, +48.9% from the last close, from 8 firms rating the stock in the last 90 days.
$14.40consensus 12-month target, +48.9% from the last close
Now $9.67Avg $14.40
Low $10High $16
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 12 | H.C. Wainwright | $16 | +65.5% |
| Oct 12 | J.P. Morgan | $15 | +55.1% |
| Oct 6 | BTIG | $16 | +65.5% |
| Oct 1 | H.C. Wainwright | $16 | +65.5% |
| Oct 1 | BTIG | $16 | +65.5% |
+4.6%average 20-day move after past Neutral readings
+16.9%average move over the next 20 trading days in the last 5 years
±9.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Absci seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Absci averaged +16.9% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +10.6% | 5 of 5 |
| Next 10 trading days | +4.3% | 3 of 5 |
| Next 15 trading days | +16.8% | 4 of 5 |
| Next 20 trading days | +16.9% | 4 of 5 |
| Next 30 trading days | −13.8% | 1 of 5 |
For scale, ABSI’s typical 20-trading-day move in either direction is about 16.4%.
Absci market cap and key statistics
Absci’s market cap is $1.64B and revenue of $1.56M over the last twelve months.
Valuation
- Market cap
- $1.64B
- EPS, TTM
- −$0.79
- Gekko Fair Value
- $10.49
Trading
- Volume
- 2.86M
- Avg volume, 20 days
- 4.67M
- 52-week high
- $12.06
- 52-week low
- $2.24
- Shares outstanding
- 171.6M
Financials
- Revenue, TTM
- $1.56M
- Profit margin
- 0%
- Return on equity
- -57.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.28
- Typical daily move
- ±9.6%
- Typical 20-day move
- ±16.4%
Absci stock news this week
Coverage of Absci this week reads positive: 3 positive, 2 neutral and 0 negative headlines.
- Absci (NASDAQ:ABSI) Stock Price Target Raised at JPMorgan Chase & Co.MarketBeat, Oct 12
- Absci (NASDAQ:ABSI) Stock Rating Reaffirmed as Buy by HC WainwrightMarketBeat, Oct 12
- Absci Corp. Advanced Charts | ABSIBarron's, Oct 8
- Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)Defense World, Oct 8
- Insiders See US$933.2k Investment In Absci Jump Last WeekMoomoo, Oct 7
- Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's WhyMarketBeat, Oct 6
Absci peers
Absci’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Absci stock FAQ
What is Absci’s market cap?
Absci’s market cap is $1.64B at the Oct 12, 2026 close of $9.67, with 171.6M shares outstanding.
What is the Absci stock forecast?
The consensus analyst 12-month price target for Absci is $14.40, +48.9% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Absci stock overvalued or undervalued?
On Gekko’s estimate Absci is undervalued: the Oct 12, 2026 close of $9.67 is 7.8% below Gekko Fair Value of $10.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Absci report earnings next?
Absci is expected to report on Nov 16, 2026 (35 days away). Analysts expect earnings of −$0.19 per share on revenue of $698K. Absci beat the earnings estimate in 2 of its last 8 reports, moving 10.1% on average across the report.
What is Absci’s 52-week high and low?
Absci’s 52-week high is $12.06 and its 52-week low is $2.24; it closed at $9.67 on Oct 12, 2026, +141.1% over the past year. Over the last five years the shares peaked at $18.12 on Nov 8, 2021.
Is Absci stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Absci the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.